Skip to search formSkip to main contentSkip to account menu

daclatasvir 90 MG Oral Tablet

Known as: DACLATASVIR 90MG TAB, DACLATASVIR 90MG TAB [VA Product], daclatasvir 90 MG (as daclatasvir dihydrochloride 99 mg) Oral Tablet 
National Institutes of Health

Related topics

Related topics

5 relations

Broader (1)

Antiviral Agents
Breast Cancer Resistance Protein Inhibitors [MoA]Hepatitis COral Tabletdaclatasvir

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Health-related quality of life on the clinical course of patients with chronic hepatitis C receiving daclatasvir/asunaprevir therapy: A prospective observational study comparing younger (<70) and…
Interferon-free direct acting antiviral agent regimens for chronic hepatitis C (CHC) have been developed. These regimens have… 
2017
2017
Favorable efficacy of daclatasvir plus asunaprevir in treatment of elderly Japanese patients infected with HCV genotype 1b aged 70 and older
The combination of daclatasvir and asunaprevir is efficacious in the treatment of hepatitis C virus (HCV) infection, but its… 
2016
2016
Daclatasvir + asunaprevir versus sofosbuvir/ledipasvir for hepatitis C genotype 1 in Japanese patients: an indirect comparison.
AIM To compare daclatasvir + asunaprevir (DCV + ASV) versus sofosbuvir/ledipasvir (SOF/LDV) for hepatitis C virus genotype 1b in… 
2016
2016
Su1428 Daclatasvir and Sofosbuvir Therapy for Patients with Decompensated Cirrhosis or Post-Liver Transplant HCV Recurrence and Advanced Fibrosis or Cirrhosis: United States Multicenter Treatment…
2016
2016
CP-049 Effectiveness of sofosbuvir based interferon free treatment regimens for chronic hepatitis C virus infection
Background Interferon free oral therapies have become elective treatment for chronic hepatitis C virus (HCV) infection… 
2016
2016
Estimating the cost‐effectiveness of daclatasvir plus asunaprevir in difficult to treat Japanese patients chronically infected with hepatitis C genotype 1b
Standard of care for chronic hepatitis C in Japan is currently a pegylated interferon (IFN)‐α + ribavirin (PR)‐based regimen… 
2015
2015
Daclatasvir/Asunaprevir併用療法におけるウイルス学的治療効果とPCR-Invader法による薬剤耐性変異測定値との関連性
2015
2015
Folgekomplikationen verhindert, Morbidität gesenkt
  • Yuri Sankawa
  • MMW - Fortschritte der Medizin
  • 2015
  • Corpus ID: 195341110
_ Allein in Deutschland könnten Modellrechnungen zufolge bis zum Jahr 2030 lediglich durch die Steigerung der therapeutischen E… 
2015
2015
Emergence of hepatitis C virus NS5A L31V plus Y93H variant upon treatment failure of daclatasvir and asunaprevir is relatively resistant to ledipasvir and NS5B polymerase nucleotide inhibitor GS…
BackgroundResistance-associated variants (RAVs) emerge at multiple positions spanning hepatitis C virus (HCV) NS3/4A and NS5A… 
2014
2014
Daclatasvir + Asunaprevir: First Global Approval
The combination of daclatasvir + asunaprevir [Daklinza® + Sunvepra® (Japan)], two direct-acting antiviral agents, has been… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)